Etidaligide - Valerio Therapeutics
Alternative Names: AsiDNA; Dbait; Dbait32H; DNA bait; DNA repair therapeutic - Valerio Therapeutics; DSB bait; DT-01; DT1Latest Information Update: 04 Oct 2024
At a glance
- Originator DNA Therapeutics
- Developer Curie Institute; Gustave Roussy; Valerio Therapeutics
- Class Antineoplastics; DNA; Immunotherapies
- Mechanism of Action DNA repair enzyme inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Breast cancer; Glioma; Malignant melanoma; Ovarian cancer; Prostate cancer
- Phase I Solid tumours
Most Recent Events
- 20 Oct 2023 Onxeo suspends the phase I/II REVOCAN trial in Ovarian cancer (Second-line therapy or greater) in France (Parenteral) (NCT04826198)
- 20 Oct 2023 Efficacy and adverse events data from a phase I/II REVOCAN trial in Ovarian cancer presented at the 48th European Society for Medical Oncology Congress (ESMO-2023)
- 20 Feb 2023 Phase-I/II clinical trials in Breast cancer (Combination therapy, Late-stage disease, Metastatic disease, Recurrent, Second-line therapy or greater) in USA (IV, Infusion) (NCT05700669)